Richard N. Rosenthal, MD discusses a randomized clinical trial demonstrating the efficacy of an implantable buprenorphine-releasing device for treating opioid use disorder.

Nearly all women experience some element of nausea and vomiting during their pregnancies. In this podcast we review the entire spectrum of disease all the way up to hyperemesis gravidarum and how to provide care for women experiencing these problems.

Article discussed in this episode:

Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy

Interview with Freddie C. Hamdy, MD, FRCSEd(Urol), and Jenny L Donovan, PhD, FMedSci, authors of Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Helping Decision Making for Patients and Their Physicians

Interview with Alex R Kemper, MD, MPH, MS, Task Force member and co-author of Interventions to Prevent Child Maltreatment: US Preventive Services Task Force Recommendation Statement

Interview with Neil Skolnik, M.D., author of Reexamining Recommendations for Treatment of Hypercholesterolemia in Older Adults

Interview with Benjamin Tolchin, MD, MS, author of Treatment of Patients With Psychogenic Nonepileptic Attacks

Interview with Alan Leshner, PhD, author of Medication-Based Treatment to Address Opioid Use Disorder

Interview with Claire J. Creutzfeldt, MD, author of Treatment Decisions for a Future Self: Ethical Obligations to Guide Truly Informed Choices

Rotch Library - KBP3067.I36 2017

With the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic, individuals with preexisting chronic health conditions such as hypertension, diabetes, and cardiovascular disease have been identified as particularly vulnerable. These patients are also more likely than the general population to be taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 gains entry into cells via binding to the angiotensin-converting enzyme 2 (ACE2) receptor, concerns have been raised that these therapies might facilitate the transmission of the virus or affect outcomes adversely. Given that ACEI and ARB therapies are known to provide benefit for the underlying conditions treated, stopping ACEI/ARB therapy carries risks. Moreover, local inactivation of the renin-angiotensin-aldosterone system may have protective effects against the development and progression of acute lung failure. In the absence of clinical evidence of benefit or risk of ACEIs/ARBs, current societal statements recommend against discontinuing these drugs other than for standard clinical indications. Robust clinical data are needed to clarify the effect of ACEIs/ARBs on SARS-CoV-2 infection.